Prognostic factors in elderly patients with acute myelogenous leukemia: a single center study in Japan

Leukemia & Lymphoma
Yasuhito NannyaAtsushi Togawa

Abstract

We retrospectively analyzed data of 47 patients aged 60 years or older, hospitalized in our institution with the diagnosis of acute myelogenous leukemia (AML), and searched for prognostic factors. Induction with anthracyclines significantly correlated with better complete remission (CR) rate (P = 0.0016) and overall survival (OS) (P < 0.001). Another factor significantly affecting CR rate was higher age (> 70 years) (P = 0.042). Therapy-non-related factors predictive for shorter OS in univariate analyses were age older than 70 years (P = 0.003), percentage of blasts in bone marrow more than 80% (P = 0.048), serum lactate dehydrogenase level higher than 250 U l(-1) (P = 0.032). In stepwise cox proportional hazard regression model, all the four factors predictive for poor OS remained to be independently and significantly prognostic for shorter OS. Only two patients receiving anthracyclines died within 30 days and the frequency was not different from that in patients not receiving anthracyclines. The use of anthracyclines as induction therapy is recommended even in the elderly patients.

References

Jan 1, 1990·Hematological Oncology·J TuckerT A Lister
Feb 1, 1995·British Journal of Haematology·M B VidrialesD Borrego
Jan 1, 1994·British Journal of Haematology·M BaudardR Zittoun
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W HiddemannT Büchner

❮ Previous
Next ❯

Citations

Jan 14, 2003·Hematological Oncology
Sep 28, 2006·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Martin PinquartUlrich Wedding
May 13, 2006·Leukemia & Lymphoma·Rony M Abou-JawdeMatt Kalaycio
Feb 6, 2008·American Journal of Hematology·Kebede HusseinDaniel Weisdorf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.